BIOGEN for BIOGEN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Health Issues HCR
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committe |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Medicare/Medicaid MMM
1) Comparative effectiveness provisions -- supporting increased transparency/reporting requirements. 2) Physician gift disclosure provisions 3) Hospital Outpatient Prospective Payment System rule -- Oppose CMS proposal to reduce hospital outpatient reimbursment rates for certain pharmaceuticals from ASP +5 to ASP +4.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.